Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $352.1 million.

  • Kiniksa Pharmaceuticals International's Cash & Equivalents rose 5734.29% to $352.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 5734.29%. This contributed to the annual value of $183.6 million for FY2024, which is 7005.48% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Cash & Equivalents of $352.1 million as of Q3 2025, which was up 5734.29% from $307.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Cash & Equivalents' 5-year high stood at $352.1 million during Q3 2025, with a 5-year trough of $108.0 million in Q4 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Cash & Equivalents value was $200.7 million (recorded in 2022), while the average stood at $203.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 4486.24% in 2022, then surged by 7005.48% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cash & Equivalents (Quarter) stood at $122.5 million in 2021, then increased by 0.2% to $122.7 million in 2022, then fell by 12.03% to $108.0 million in 2023, then soared by 70.05% to $183.6 million in 2024, then skyrocketed by 91.8% to $352.1 million in 2025.
  • Its last three reported values are $352.1 million in Q3 2025, $307.8 million for Q2 2025, and $268.3 million during Q1 2025.